Dr. Eric Topol pointed out that while initial findings on generative AI in clinical settings are promising, they may not withstand the complexities of real-world clinical practice.
The more the use of AI in healthcare and healthcare research becomes mainstream, the more the risks associated with AI-powered analysis evolve — and the greater the potential for breakdowns in consumer trust.
In this episode, we're joined by Kathryn Schubert, president and CEO of the Society for Women's Health Research. Schubert discusses the trends in women's health that defined 2024 and what we can expect in the coming year.
Through collaboration between regulators and healthcare stakeholders, telehealth prescribing can continue to expand treatment access while maintaining proven safety standards.
These valuable caregivers do not need false claims, empty promises, or even more technology to stay on top of. They need access to health education and literacy, healthy food, and seamless self-efficacy tools.
In this episode, we look at the reelection of Trump and how it will affect healthcare. We address the 340B drug discount program and the fact that J&J is suing the federal government over it. We also discuss how health systems in upstate New York are trying to provide pharmacy services given that many local pharmacies are shutting down.
No comments